Physician profile
Kylee Rae Meyer
NPI 1407300601
$4,139.97
in general payments reported to CMS, 2019-2025
33 companies · $636 in 2025
The $636 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,080 · 2022: $888 · 2023: $537 · 2024: $998 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,159.74 | 2021-2025 | |
| Novo Nordisk INC | $396.48 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $387.76 | 2021-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $353.73 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $268.71 | 2023-2025 | |
| Astellas Pharma US INC | $242.80 | 2021-2022 | |
| Lilly USA, LLC | $178.28 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $163.77 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.42 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $93.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.92 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $78.91 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $72.20 | 2021-2022 | |
| Abbott Laboratories | $63.45 | 2024-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $61.29 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.84 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $48.78 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $39.77 | 2021-2022 | |
| Grifols USA, LLC | $30.58 | 2023-2024 | Prolastin-C Liquid |
| Avanir Pharmaceuticals, INC. | $24.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.78 | 2021 | |
| Eisai INC. | $23.56 | 2025 | |
| Myriad Women'S Health, INC. | $20.53 | 2023 | |
| Sumitomo Pharma America, INC. | $20.52 | 2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $20.43 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.32 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.65 | 2025 | Uptravi, Opsumit |
| Biogen, INC. | $16.44 | 2021 | |
| Vanda Pharmaceuticals INC. | $13.79 | 2025 | Fanapt |
| Exact Sciences Corporation | $12.84 | 2023 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $12.79 | 2022 | |
| Glaxosmithkline, LLC. | $12.58 | 2022 | |
| Galderma Laboratories, L.P. | $11.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylee Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.